Oruka Therapeutics, Inc. Selling, General and Administrative Expense
Oruka Therapeutics, Inc. (ORKA) reported Selling, General and Administrative Expense of $950.00 thousand for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-11-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2014-11-12
- Oruka Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2014-09-30 was $950.00K, a 6.03% decline year-over-year.
- Oruka Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2014-06-30 was $1.01M, a 5.67% increase year-over-year.
- Oruka Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2014-03-31 was $1.08M, a 21.71% increase year-over-year.
- Oruka Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2013-12-31 was $1.16M, a 79.01% increase year-over-year.
- Oruka Therapeutics, Inc. selling, general and administrative expense for fiscal 2013 was $4.01M, a 24.33% increase from fiscal 2012.
- Oruka Therapeutics, Inc. selling, general and administrative expense for fiscal 2012 was $3.23M, a 36.05% decline from fiscal 2011.
- Oruka Therapeutics, Inc. selling, general and administrative expense for fiscal 2011 was $5.05M, a 16.86% decline from fiscal 2010.
- Oruka Therapeutics, Inc. selling, general and administrative expense for fiscal 2010 was $6.07M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 114 month | Selling, General and Administrative Expense 117 month | Selling, General and Administrative Expense 120 month | Selling, General and Administrative Expense 123 month | Selling, General and Administrative Expense 126 month | Selling, General and Administrative Expense 129 month | Selling, General and Administrative Expense 132 month | Selling, General and Administrative Expense 135 month | Selling, General and Administrative Expense 138 month | Selling, General and Administrative Expense 141 month | Selling, General and Administrative Expense 144 month | Selling, General and Administrative Expense 147 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-09-30 | $950.00K 10-Q · filed 2014-11-12 | $1.96M derived: sum of 2 quarters · filed 2014-11-12 | $3.04M 10-Q · filed 2014-11-12 | $4.20M derived: sum of 4 quarters · filed 2014-11-12 | ||||||||||||
| 2014-06-30 | $1.01M 10-Q · filed 2014-08-13 | $2.09M 10-Q · filed 2014-08-13 | $3.25M derived: sum of 3 quarters · filed 2014-08-13 | $4.26M derived: sum of 4 quarters · filed 2014-11-12 | ||||||||||||
| 2014-03-31 | $1.08M 10-Q · filed 2014-05-13 | $2.24M derived: sum of 2 quarters · filed 2014-05-13 | $3.25M derived: sum of 3 quarters · filed 2014-11-12 | $4.21M derived: sum of 4 quarters · filed 2014-11-12 | $47.68M 10-Q · filed 2014-05-13 | |||||||||||
| 2013-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-20 | $2.17M derived: sum of 2 quarters · filed 2014-11-12 | $3.12M derived: sum of 3 quarters · filed 2014-11-12 | $4.01M 10-K · filed 2014-03-20 | $46.59M 10-K · filed 2014-03-20 | |||||||||||
| 2013-09-30 | $1.01M 10-Q · filed 2014-11-12 | $1.96M derived: sum of 2 quarters · filed 2014-11-12 | $2.85M 10-Q · filed 2014-11-12 | $3.50M derived: sum of 4 quarters · filed 2014-11-12 | $45.44M 10-Q · filed 2013-11-13 | |||||||||||
| 2013-06-30 | $952.00K 10-Q · filed 2014-08-13 | $1.84M 10-Q · filed 2014-08-13 | $2.49M derived: sum of 3 quarters · filed 2014-08-13 | $3.26M derived: sum of 4 quarters · filed 2014-08-13 | $44.42M 10-Q · filed 2013-08-13 | |||||||||||
| 2013-03-31 | $889.00K 10-Q · filed 2014-05-13 | $1.54M derived: sum of 2 quarters · filed 2014-05-13 | $2.31M derived: sum of 3 quarters · filed 2014-05-13 | $3.13M derived: sum of 4 quarters · filed 2014-05-13 | $43.47M 10-Q · filed 2013-05-13 | |||||||||||
| 2012-12-31 | $648.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-20 | $1.42M derived: sum of 2 quarters · filed 2014-03-20 | $2.24M derived: sum of 3 quarters · filed 2014-03-20 | $3.23M 10-K · filed 2014-03-20 | $42.58M 10-K · filed 2013-03-21 | |||||||||||
| 2012-09-30 | $772.00K 10-Q · filed 2013-11-13 | $1.59M derived: sum of 2 quarters · filed 2013-11-13 | $2.58M 10-Q · filed 2013-11-13 | $3.62M derived: sum of 4 quarters · filed 2013-11-13 | $41.94M 10-Q · filed 2012-11-13 | |||||||||||
| 2012-06-30 | $823.00K 10-Q · filed 2013-08-13 | $1.81M 10-Q · filed 2013-08-13 | $2.85M derived: sum of 3 quarters · filed 2013-08-13 | $4.13M derived: sum of 4 quarters · filed 2013-08-13 | $41.16M 10-Q · filed 2012-08-13 | |||||||||||
| 2012-03-31 | $984.00K 10-Q · filed 2013-05-13 | $2.02M derived: sum of 2 quarters · filed 2013-05-13 | $3.31M derived: sum of 3 quarters · filed 2013-05-13 | $4.52M derived: sum of 4 quarters · filed 2013-05-13 | $40.34M 10-Q · filed 2012-05-14 | |||||||||||
| 2011-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-21 | $2.33M derived: sum of 2 quarters · filed 2013-03-21 | $3.53M derived: sum of 3 quarters · filed 2013-03-21 | $5.05M 10-K · filed 2013-03-21 | $39.36M 10-K · filed 2012-03-27 | |||||||||||
| 2011-09-30 | $1.29M 10-Q · filed 2012-11-13 | $2.50M derived: sum of 2 quarters · filed 2012-11-13 | $4.01M 10-Q · filed 2012-11-13 | $5.50M derived: sum of 4 quarters · filed 2012-11-13 | $38.32M 10-Q · filed 2011-11-14 | |||||||||||
| 2011-06-30 | $1.21M 10-Q · filed 2012-08-13 | $2.72M 10-Q · filed 2012-08-13 | $4.21M derived: sum of 3 quarters · filed 2012-08-13 | $5.59M derived: sum of 4 quarters · filed 2012-08-13 | $37.03M 10-Q · filed 2011-08-15 | |||||||||||
| 2011-03-31 | $1.51M 10-Q · filed 2012-05-14 | $3.00M derived: sum of 2 quarters · filed 2012-05-14 | $4.38M derived: sum of 3 quarters · filed 2012-05-14 | $5.95M derived: sum of 4 quarters · filed 2012-05-14 | ||||||||||||
| 2010-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-27 | $2.87M derived: sum of 2 quarters · filed 2012-03-27 | $4.44M derived: sum of 3 quarters · filed 2012-03-27 | $6.07M 10-K · filed 2012-03-27 | ||||||||||||
| 2010-09-30 | $1.38M 10-Q · filed 2011-11-14 | $2.95M derived: sum of 2 quarters · filed 2011-11-14 | $4.58M 10-Q · filed 2011-11-14 | |||||||||||||
| 2010-06-30 | $1.57M 10-Q · filed 2011-08-15 | $3.20M 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |